VolitionRX (VNRX) Rating Reiterated by HC Wainwright

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday. They currently have a $10.00 target price on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 171.74% from the stock’s previous close.

VolitionRX (VNRX) traded up $0.06 during trading hours on Monday, hitting $3.68. The stock had a trading volume of 150,729 shares, compared to its average volume of 146,185. VolitionRX has a 1-year low of $2.08 and a 1-year high of $4.77. The company has a market cap of $93.67, a price-to-earnings ratio of -7.23 and a beta of -1.46.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01).

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of VolitionRX by 177.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,376 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 19,414 shares during the period. Leisure Capital Management acquired a new stake in shares of VolitionRX in the 3rd quarter valued at about $193,000. Finally, Lagoda Investment Management L.P. raised its stake in shares of VolitionRX by 6.4% in the 3rd quarter. Lagoda Investment Management L.P. now owns 3,356,754 shares of the medical research company’s stock valued at $8,828,000 after purchasing an additional 201,062 shares during the period.

WARNING: “VolitionRX (VNRX) Rating Reiterated by HC Wainwright” was posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/29/volitionrx-vnrx-rating-reiterated-by-hc-wainwright.html.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply